



The 8th International Electronic Conference on Medicinal Chemistry (ECMC 2022)

01-30 NOVEMBER 2022 | ONLINE

Anthrarufin and its anionic moieties as potential inhibitors of HIV-1 reverse transcriptase (RT)

Chaired by DR. ALFREDO BERZAL-HERRANZ;
Co-Chaired by PROF. DR. MARIA EMÍLIA SOUSA



pharmaceuticals



Svetlana Jeremić¹, Ana Kesić², Jelena Đorović Jovanović², Zoran Marković²





¹ *State University of Novi Pazar, University of Novi Pazar. Vuka Karadzica 9, 36300 Novi Pazar, Serbia*

² *University of Kragujevac, Institute for Information Technologies, Jovana Cvijica bb, 34000 Kragujevac, Serbia*



*Correspondence: sjeremic@np.ac.rs

GRAFICAL ABSTRACT:



ECMC
2022

The 8th International Electronic
Conference on Medicinal Chemistry

01-30 NOVEMBER 2022 | ONLINE

ABSTRACT:

INTRODUCTION

At the end of the last century, it was revealed that quinones with one, two, and three aromatic rings could inhibit HIV-1 protease, an enzyme crucial for HIV (Human Immunodeficiency Virus) replication. Since HIV-1 protease acts as key target for AIDS medications (Acquired immunodeficiency syndrome), the development of efficient inhibitor of this protein would lead to the increasing of the medical treatment and decreasing of the drug resistance. Later research revealed that simply hydroxyquinones can block HIV-1 protease at the micromolar level, which enabled a direction for the creation of HIV medications. Anthrarufin (1,5-dihydroxy-9,10-anthraquinone) is an anthraquinone that posses a moderate antioxidative capacity and antimalaric activity. In the work presented here, the inhibitory activity of the anthrarufin and its anions toward HIV-1 reverse transcriptase was for the first time examined and compared with the inhibitory activity of the well-known drugs dolutegravir, nevirapine and rilpivirine.

METHODOLOGY

In this study, molecular docking simulations were used to examine the molecular interactions between anthrarufin, its monoanion and dianion as ligands, and the HIV-1 reverse transcriptase (HIV-1 RT) as target protein. Using AGFR software, the binding site of the HIV-1 RT is identified. The three-dimensional crystal structure of HIV-1 RT is downloaded from the Protein Data Bank (PDB ID: 2ZD1). Dolutegravir, nevirapine, anthrarufin, anthrarufin-anion and anthrarufin-dianion are used as ligands in the molecular docking simulations together with rilpivirine (TMC278), a non-nucleoside inhibitor of estimated protein. The AutoDock 4.0 program is used for molecular docking simulations.

RESULTS AND DISCUSSION

Anthrarufin, its monoanion and dianion can be considered as a potential HIV-1 RT inhibitors because they have similar inhibitory potency to other ligands under consideration, according to the results of the free energy of binding (ΔG_{bind}) and inhibition constant (K_i) values.

Keywords: Reverse transcriptase (RT), Anthrarufin, molecular docking, HIV-1 .

ECMC
2022

The 8th International Electronic
Conference on Medicinal Chemistry
01-30 NOVEMBER 2022 | ONLINE

INTRODUCTION

- ✓ At the end of the last century, it was revealed that quinones with one, two, and three aromatic rings could inhibit HIV-1 protease, an enzyme crucial for HIV (Human Immunodeficiency Virus) replication [1].
- ✓ Since HIV-1 protease acts as key target for AIDS medications (Acquired immunodeficiency syndrome), the development of efficient inhibitor of this protein would lead to the increasing of the medical treatment and decreasing of the drug resistance.
- ✓ Later research revealed that simply hydroxyquinones can block HIV-1 protease at the micromolar level, which enabled a direction for the creation of HIV medications.
- ✓ Polyhydroxy anthraquinones can bind to proteins in different ways, both due to hydroxyl groups and due to the polycyclic aromatic π -electron structure. It is believed that those binding interactions are responsible for the detected inhibition of HIV-1 proteinase by anthraquinones.

[1] Brinkworth RL, Fairlie DP (1995) *Biochimica et Biophysica Acta*, No1253 5-8




Fig. 1. 3D structure of HIV-1 reverse transcriptase (RT) (PDB ID: 2ZD1)

- ✓ In this study, molecular docking simulations were used to examine the molecular interactions between anthraruflin, its monoanion and dianion as ligands, and the HIV-1 reverse transcriptase (HIV-1 RT) as target protein (**Fig. 1 and Fig.2**).
- ✓ Recently, integrase chain inhibitors, especially dolutegravir, have shown significantly higher safety and efficacy and have become the main agents of choice in HIV therapy. Dolutegravir is an antiretroviral drug belonging to the class of HIV integrase strand transfer inhibitors (ISTIs) [2].
- ✓ The inhibition potency of anthraruflin and its anionic species are compared with inhibition potency of dolutegravir, nevirapine and rilpivirine, a conventional a non-nucleoside inhibitor of estimated protein [3,4].




Fig. 2. The structural formulas of the investigated compounds

[2] McCormack PL.(2014) *Drugs*, 74 (1) 1241–1252.

[3] Frey KM et al. (2015) *J Med Chem*, 58 (6) 2737–2745.

[4] Johnson BC et al. (2012) *Retrovirology* 9, No 99.

**ECMC
2022**

**The 8th International Electronic
Conference on Medicinal Chemistry**
01–30 NOVEMBER 2022 | ONLINE

- ✓ **DFT method, M06-2X/6-311++G(d,p)** (Gaussian 09 program package) – optimization of the structures of terpyridine metal complexes
- ✓ **Protein Data Bank (PDB ID: 2ZD1)** - three-dimensional (3D) crystal structure of PBP1a protein [5]
- ✓ **Discovery Studio 4.0** - protein is released from the co-crystallized ligand, water molecules, and cofactors.
- ✓ **AGFR (AutoGridFR) software** – establishing of the affinity maps of the target protein
- ✓ **AutoDock 4.0 software2** – molecular docking simulations [6]
- ✓ **BIOVIA Discovery Studio** - analysis of molecular docking simulation results and visualizations of predicted protein-ligand interactions

[5] Das K et al. (2007) *wwPDB*, PDB ID : 2ZD1.

[6] Morris GM et al. (2009) *J Comput Chem*, 30 (16) 2785-2791.

RESULTS AND DISCUSSION

ECMC
2022

The 8th International Electronic
Conference on Medicinal Chemistry

01-30 NOVEMBER 2022 | ONLINE

✓ In **Fig. 3.** are presented interactions achieved in all molecular docking simulations. The obtained interactions are of different types of interactions. The most represented of them are formations of hydrogen bonds.




Fig. 3 Docking positions of the RT protein with anthrurufin dianion (a), dolutegravir (b), nevirapine (c) and rilpirivine (d).

- ✓ The inhibitory potency of preferred compounds can be estimated based on the thermodynamical parameters obtained from molecular docking simulations: free energy of binding (ΔG_{bind}) and inhibition constant (K_i).

Table1: The important thermodynamical parameters from molecular docking simulations between RT protein and selected compounds (Fig. 3)

Ligand	ΔG_{bind} (kcalmol ⁻¹)	K_i (nM)
Anthrarufin	-7.44	3.53
Anthrarufin anion	-7.43	3.57
Anthrarufin dianion	-7.78	1.97
Dolutegravir	-9.01	0.248
Nevirapine	-6.41	20.17
Rilpivirine	-9.27	0.167

CONCLUSIONS

- ✓ Anthrarufin dianion has higher inhibition potency than anthrarufin anion and anthrarufin
- ✓ Anthrarufin and both of their anionic species have lower inhibition potency than dolutegravir and rilpivirine, but higher inhibition potency than nevirapine.
- ✓ All six estimated inhibitors interact with RT protein over three common amino acids: Pro140, Gln 161 and Gln182.
- ✓ Among the most important interactions are conventional hydrogen bonds, and interactions involving π -electrons from aromatic rings.
- ✓ Anthrarufin, its monoanion and dianion can be considered as a potential HIV-1 RT inhibitors
- ✓ The inhibitory activity of the anthrarufin and its anions toward HIV-1 reverse transcriptase was for the first time examined and compared with the inhibitory activity of the well-known drugs dolutegravir, nevirapine and rilpivirine. Therefore this is the first time that the activities between the known drugs and the here investigated anthrarufin moieties are compared and presented.

ACKNOWLEDGMENTS

The authors are grateful to the Ministry of Education, Science and Technological Development of the Republic of Serbia (Agreement No. 451-03-68/2022-14/200252 and No. 451-03-68/2022-14/200378.)



MINISTRY OF EDUCATION,
SCIENCE AND TECHNOLOGICAL DEVELOPMENT



STATE UNIVERSITY OF
NOVI PAZAR



INSTITUTE FOR INFORMATION
TECHNOLOGIES KRAGUJEVAC

ECMC
2022

The 8th International Electronic
Conference on Medicinal Chemistry

01-30 NOVEMBER 2022 | ONLINE